Resumen
What is the efficacy and safety of atezolizumab with oxaliplatin and 5-fluorouracil followed by atezolizumab for localized esophageal or gastroesophageal junction adenocarcinomas before surgical resection? In this non-randomized controlled clinical trial, the observed pathological complete response (downstaging to ypT0N0M0) after surgery was 11.1%. The median overall survival was 38.6 months, and the median disease-free survival was 28.8 months. Two patients had grade 4 treatment-related adverse events. These findings suggest that atezolizumab with oxaliplatin and 5-fluorouracil for the treatment of localized, resectable adenocarcinoma of the esophagus or gastroesophageal junction showed moderate efficacy with an acceptable safety profile and warrants further investigation.